Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
Background
This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?
Background
This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).
Background
This week, we will discuss how the CONFIDENCE trial gets nephrology closer to the magic CKD polypill of CKD.
